Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection against SIV and HIV. Persistent, recombinant herpesviruses are being used in monkeys to try to match the degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been promising but the absence of anti-Env antibody responses from the recombinant herpesviruses has been a glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the promise of this approach.

Public Health Relevance

The proposed experiments will allow a greater appreciation of the potential for recombinant herpesviruses in particular, and persistent vectors in general, for their capacity to provide protection against AIDS virus exposure. If shown to be significantly better than other vaccine approaches, it will shape the emphasis for ongoing preclinical vaccine discovery research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56AI063928-06
Application #
8481631
Study Section
HIV/AIDS Vaccines Study Section (VACC)
Program Officer
Pensiero, Michael N
Project Start
2004-12-01
Project End
2012-11-30
Budget Start
2012-06-18
Budget End
2012-11-30
Support Year
6
Fiscal Year
2012
Total Cost
$604,524
Indirect Cost
$259,082
Name
Harvard University
Department
Veterinary Sciences
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115